Sputum-derived Cellular Targets After Xolair (Omalizumab)
Clinical trial NCT02658877 · TERMINATED
Trial details
- NCT number
- NCT02658877
- Sponsor
- NYU Langone Health
- Status
- TERMINATED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-01
- Primary completion
- 2018-07-19
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.